B‐lineage antigens that are useful to substitute <scp>CD19</scp> for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after <scp>CD19</scp> targeting

Abstract

We conclude that the addition of CD22, CD24, and iCD79a to the conventional antibody panel and their application together with CD10 allow for the identification of B-lineage compartment including residual tumor blasts, for MFC-MRD searching in virtually all patients with BCP-ALL after CD19-directed treatment.